...
cccc-img

C4 Therapeutics Inc, Common Stock

CCCC

NSQ

$3.95

+$0.1

(2.6%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$271.41M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
3.73M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
3.06
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$3.61 L
$11.88 H
$3.95

About C4 Therapeutics Inc, Common Stock

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameCCCCSectorS&P500
1-Week Return-9.82%-2.12%-3%
1-Month Return-2.47%-3.42%-0.73%
3-Month Return-37.8%-11.13%2.87%
6-Month Return-2.47%-5.74%7.17%
1-Year Return-9.2%3.97%25.31%
3-Year Return-87.46%1.05%28.38%
5-Year Return-84.5%34.37%81.89%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue21.38M33.20M45.78M31.10M20.76M[{"date":"2019-12-31","value":46.7,"profit":true},{"date":"2020-12-31","value":72.5,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":67.92,"profit":true},{"date":"2023-12-31","value":45.33,"profit":true}]
Cost of Revenue47.66M77.47M2.91M7.57M117.71M[{"date":"2019-12-31","value":40.49,"profit":true},{"date":"2020-12-31","value":65.81,"profit":true},{"date":"2021-12-31","value":2.47,"profit":true},{"date":"2022-12-31","value":6.43,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit(26.28M)(44.27M)42.88M23.52M(96.95M)[{"date":"2019-12-31","value":-61.3,"profit":false},{"date":"2020-12-31","value":-103.25,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":54.86,"profit":true},{"date":"2023-12-31","value":-226.11,"profit":false}]
Gross Margin(122.93%)(133.37%)93.65%75.65%(467.09%)[{"date":"2019-12-31","value":-131.26,"profit":false},{"date":"2020-12-31","value":-142.41,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":80.78,"profit":true},{"date":"2023-12-31","value":-498.76,"profit":false}]
Operating Expenses56.83M93.64M127.92M160.63M159.79M[{"date":"2019-12-31","value":35.38,"profit":true},{"date":"2020-12-31","value":58.3,"profit":true},{"date":"2021-12-31","value":79.64,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":99.48,"profit":true}]
Operating Income(35.45M)(60.45M)(82.13M)(129.53M)(139.03M)[{"date":"2019-12-31","value":-3545200000,"profit":false},{"date":"2020-12-31","value":-6044900000,"profit":false},{"date":"2021-12-31","value":-8213400000,"profit":false},{"date":"2022-12-31","value":-12953400000,"profit":false},{"date":"2023-12-31","value":-13903100000,"profit":false}]
Total Non-Operating Income/Expense3.99M(7.35M)(3.52M)2.72M14.41M[{"date":"2019-12-31","value":27.67,"profit":true},{"date":"2020-12-31","value":-50.97,"profit":false},{"date":"2021-12-31","value":-24.39,"profit":false},{"date":"2022-12-31","value":18.86,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(33.30M)(66.96M)(83.89M)(128.18M)(131.21M)[{"date":"2019-12-31","value":-3329500000,"profit":false},{"date":"2020-12-31","value":-6696100000,"profit":false},{"date":"2021-12-31","value":-8389200000,"profit":false},{"date":"2022-12-31","value":-12817500000,"profit":false},{"date":"2023-12-31","value":-13121300000,"profit":false}]
Income Taxes804.00K(626.00K)2.15M(1.68M)1.28M[{"date":"2019-12-31","value":37.48,"profit":true},{"date":"2020-12-31","value":-29.18,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-78.14,"profit":false},{"date":"2023-12-31","value":59.67,"profit":true}]
Income After Taxes(34.10M)(66.33M)(86.04M)(126.50M)(132.49M)[{"date":"2019-12-31","value":-3409900000,"profit":false},{"date":"2020-12-31","value":-6633500000,"profit":false},{"date":"2021-12-31","value":-8603700000,"profit":false},{"date":"2022-12-31","value":-12649900000,"profit":false},{"date":"2023-12-31","value":-13249300000,"profit":false}]
Income From Continuous Operations(34.10M)(66.33M)(83.89M)(128.18M)(134.92M)[{"date":"2019-12-31","value":-3409900000,"profit":false},{"date":"2020-12-31","value":-6633500000,"profit":false},{"date":"2021-12-31","value":-8389200000,"profit":false},{"date":"2022-12-31","value":-12817500000,"profit":false},{"date":"2023-12-31","value":-13492400000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(34.10M)(66.33M)(86.04M)(126.50M)(132.49M)[{"date":"2019-12-31","value":-3409900000,"profit":false},{"date":"2020-12-31","value":-6633500000,"profit":false},{"date":"2021-12-31","value":-8603700000,"profit":false},{"date":"2022-12-31","value":-12649900000,"profit":false},{"date":"2023-12-31","value":-13249300000,"profit":false}]
EPS (Diluted)-(17.69)(1.82)(2.63)(2.66)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-1769,"profit":false},{"date":"2021-12-31","value":-182,"profit":false},{"date":"2022-12-31","value":-263,"profit":false},{"date":"2023-12-31","value":-266,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

CCCC
Cash Ratio 5.90
Current Ratio 6.31

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

CCCC
ROA (LTM) -20.61%
ROE (LTM) -46.00%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

CCCC
Debt Ratio Lower is generally better. Negative is bad. 0.35
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.65

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

CCCC
Trailing PE NM
Forward PE NM
P/S (TTM) 8.28
P/B 1.12
Price/FCF NM
EV/R 2.46
EV/Ebitda NM

FAQs

What is C4 Therapeutics Inc share price today?

C4 Therapeutics Inc (CCCC) share price today is $3.95

Can Indians buy C4 Therapeutics Inc shares?

Yes, Indians can buy shares of C4 Therapeutics Inc (CCCC) on Vested. To buy C4 Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CCCC stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of C4 Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of C4 Therapeutics Inc (CCCC) via the Vested app. You can start investing in C4 Therapeutics Inc (CCCC) with a minimum investment of $1.

How to invest in C4 Therapeutics Inc shares from India?

You can invest in shares of C4 Therapeutics Inc (CCCC) via Vested in three simple steps:

  • Click on Sign Up or Invest in CCCC stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in C4 Therapeutics Inc shares
What is C4 Therapeutics Inc 52-week high and low stock price?

The 52-week high price of C4 Therapeutics Inc (CCCC) is $11.88. The 52-week low price of C4 Therapeutics Inc (CCCC) is $3.61.

What is C4 Therapeutics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of C4 Therapeutics Inc (CCCC) is

What is C4 Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of C4 Therapeutics Inc (CCCC) is 1.12

What is C4 Therapeutics Inc dividend yield?

The dividend yield of C4 Therapeutics Inc (CCCC) is 0.00%

What is the Market Cap of C4 Therapeutics Inc?

The market capitalization of C4 Therapeutics Inc (CCCC) is $271.41M

What is C4 Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of C4 Therapeutics Inc is CCCC

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top